Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | FGF2 | P09038 | 1/20 | 0.34 |
| ▸ | IDUA | P35475 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412631 | 1.00 | M6PR (0.38) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL21065667 | 1.00 | M6PR (0.38) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL13642457 | 0.89 | AKT1 (0.36) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL24694355 | 0.86 | FGF2 (0.43) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL13901005 | 0.85 | M6PR (0.41) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL21540433 | 0.85 | M6PR (0.41) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL8267592 | 0.85 | FGF2 (0.37) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL16744184 | 0.85 | M6PR (0.41) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL13814803 | 0.85 | FGF2 (0.37) | M6PRAKT1SUCNR1LGALS8FGF2 | |
| SCHEMBL18372818 | 0.85 | FGF2 (0.37) | M6PRAKT1SUCNR1LGALS8FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232193-A2 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BioMarin Pharmaceutical Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2376915-B1 | METHOD FOR DIAGNOSING MPS IIIB DISORDER | BIOMARIN PHARM INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9512161-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2015145336-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-20140378400-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION | 2014-12-25 | — | — | US | disclosed |
| US-8748401-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8486902-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-20080262228-A1 | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2006052886-A1 | METABOLITES OF CERTAIN [1,4]DIAZEPINO[6,7,1-IJ]QUINOLINE DERIVATIVES AND METHODS OF PREPARATION AND USE THEREOF | WYETH (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | UGT1A4, UGT1A3, UGT1A1 | M6PR 1208/4885AKT1 4456/4885SUCNR1 946/4885 |
| US-20140378400-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | UGT1A4, UGT1A3, UGT1A1 | M6PR 1208/4885AKT1 4456/4885SUCNR1 946/4885 |
| US-20080262228-A1 | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof | UGT1A8, CYP2C8, NQO1 | M6PR 1935/4885AKT1 3876/4885SUCNR1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.